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Twenty-two novel dipeptidyl peptidase-IV (DPP-IV) inhibitory peptides (with IC50 values <200 µM) and 
fifteen novel insulinotropic peptides were identified in a boarfish protein hydrolysate generated at 
semi-pilot scale using Alcalase 2.4L and Flavourzyme 500L. This was achieved by bioassay-driven semi-
preparative reverse phase-high performance liquid chromatography fractionation, liquid 
chromatography-mass spectrometry and confirmatory studies with synthetic peptides. The most 
potent DPP-IV inhibitory peptide (IPVDM) had a DPP-IV half maximal inhibitory concentration (IC50) 
values of 21.72 ± 1.08 µM in a conventional in vitro and 44.26 ± 0.65 µM in an in situ cell-based (Caco-
2) DPP-IV inhibition assay. Furthermore, this peptide stimulated potent insulin secretory activity (1.6-
fold increase compared to control) from pancreatic BRIN-BD11 cells grown in culture. The tripeptide 
IPV exhibited potent DPP-IV inhibitory activity (IC50: 5.61 ± 0.20 µM) comparable to that reported for 
the known DPP-IV inhibitor IPI (IC50: 5.61 µM). Boarfish proteins contain peptide sequences with 













Type 2 diabetes mellitus (T2DM) is a complex chronic metabolic condition characterised by insulin 
resistance and insufficient pancreatic insulin production resulting in hyperglycaemia. Progression of 
the disease can lead to numerous long-term micro- and macro-vascular complications which increase 
the risk of premature death (Fowler, 2011). Global data indicates that approximately 415 million 
people are currently living with T2DM and it is estimated that, if immediate interventions are not 
taken, this could reach 642 million by 2040 (IDF Atlas, 2015; WHO, 2016). In addition to its effect on 
the health and well-being of the individual, T2DM and its complications effect national economies 
through increased direct healthcare and indirect societal costs (WHO, 2016). Therefore, efforts to 
address this growing challenge have become a major global public health priority.  
Incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) stimulate the secretion of insulin in response to nutrient ingestion (Green, Gault, 
O'Harte, & Flatt, 2004). However, the incretins are rapidly degraded by dipeptidyl peptidase-IV (DPP-
IV) resulting in the loss of their insulinotropic properties (Green et al., 2004). Increasing the half-life of 
endogenous GLP-1 through development of specific DPP-IV inhibitory agents is one approach which 
has been adopted to aid glycaemic management in T2DM subjects (Li et al., 2018; Deacon, 2018). 
Numerous synthetic DPP-IV inhibitory drugs such as saxagliptin, sitagliptin, linagliptin and vildagliptin, 
are currently on the market (Power, Nongonierma, Jakeman, & FitzGerald, 2014; Aroor, Manrique-
Acevedo, & DeMarco, 2018). These drugs, which are collectively known as gliptins, are reported to 
mediate side-effects such as headaches and urinary and upper respiratory tract infections. Therefore, 
the discovery and application of natural DPP-IV inhibitory compounds with reduced or no side-effects 
and which can be consumed as part of the normal diet are the subject of much current investigation. 
Examination of the literature shows that food-derived proteins/peptides can beneficially modulate 
biomarkers of T2DM in vitro and in vivo and they are increasingly being recognised as potential natural 
biofunctional agents for the prevention and/or management of T2DM (Harnedy et al., 2018a; Harnedy 
et al., 2018b; Oseguera-Toledo, de Mejía, Reynoso-Camacho, Cardador-Martínez, & Amaya-Llano, 
 
 
2014; Promintzer & Krebs, 2006). It has been established that proteins, protein hydrolysates, peptides 
and amino acids can beneficially regulate blood glucose level. The mechanisms involved include direct 
stimulation of insulin secretion from pancreatic β-cells or by indirect means through inhibition of DPP-
IV along with stimulation of the release of the incretin hormones GLP-1 and GIP. However, the exact 
mechanism(s) and the primary sequences of the proteinaceous components involved have yet to be 
fully elucidated (Newsholme & Krause, 2012; Oseguera-Toledo et al., 2014). Peptides and amino acids 
with in vitro DPP-IV inhibitory activity have been identified from a variety of food protein sources 
including those of marine origin (Harnedy, O’Keeffe, & FitzGerald, 2015; Huang, Jao, Ho, & Hsu, 2012; 
Li-Chan, Hunag, Jao, Ho, & Hsu, 2012; McLaughlin et al., 2018; Neves et al., 2017; Neves, Harnedy, 
O’Keeffe, & FitzGerald, 2017; Wang et al., 2015; Zhang, Zhang, Wang, Chen, & Luo, 2017). 
Furthermore, the potential of food protein-derived peptides as DPP-IV inhibitors has more recently 
been investigated in situ using Caco-2 cells which express DPP-IV (Caron, Domenger, Dhulster, 
Ravallec, & Cudennec, 2017). Studies with these human intestinal epithelial cells help provide 
information on the fate of peptides in terms of cellular permeability and stability to brush border 
enzyme(s) and the potential of the peptides to subsequently inhibit soluble DPP-IV found in plasma. 
While reports have shown that amino acids such as glutamine, alanine, arginine, leucine, 
phenylalanine, valine, isoleucine and lysine have strong insulin secretory activity, limited information 
exists on peptides as insulin secretagogues (Dixon, Nolan, McClenaghan, Flatt, & Newsholme, 2003; 
Morifuji et al., 2010; Newsholme, Brennan & Bender, 2006; Power-Grant et al. 2015). To date, 
peptides derived from casein and from Palmaria palmata proteins have been shown to stimulate the 
secretion of insulin from cultured pancreatic BRIN-BD11 cells (Drummond et al., 2018; O’Harte et al., 
2016).  
In our previous study, a protein hydrolysate from boarfish generated at laboratory scale (≈10 g) using 
Alcalase 2.4L and Flavourzyme 500L had DPP-IV inhibitory and insulinotropic activity in vitro 
(Parthsarathy et al., 2019). The objective of this study was to fractionate, identify and characterize the 
peptides potentially associated with the observed DPP-IV inhibitory and insulin secretory activity in 
 
 
the boarfish protein hydrolysate generated at semi-pilot scale (≈70 kg). DPP-IV inhibition was 
determined using in vitro enzyme inhibition and in situ cell-based inhibition assays while insulin 
secretion was assessed using BRIN-BD11 cells grown in culture. 
 
2. Materials and methods  
2.1. Materials and chemicals 
Samples of minced deboned boarfish (Capros aper) meat was kindly provided by Bio-Marine 
Ingredients Ireland, Ltd., Killybegs, Co. Donegal, Ireland. H-Gly-Pro-7-amino-4–methyl coumarin (AMC) 
and Diprotin A (IPI) were purchased from Bachem Feinchemikalien (Bubendorf, Switzerland). HPLC 
grade water, acetonitrile and Kjeldahl catalyst tablets were obtained from VWR International (Dublin, 
Ireland). Electrospray ionisation (ESI) low molecular mass tune mix was from Agilent Technologies 
(Cork, Ireland). AB Enzymes (Darmstadt, Germany) and Biocatalysts Ltd (Cardiff, Wales, United 
Kingdom) kindly provided the Corolase PP and BC pepsin, respectively. Calcium chloride dihydrate 
(CaCl2.2H20), D-glucose, HEPES, hydrochloric acid (HCl), magnesium sulphate (MgSO4.7H2O), 
potassium dihydrogen orthophosphate (KH2PO4), potassium chloride (KCl), sodium bicarbonate 
(NaHCO3) and sodium chloride (NaCl) were purchased from BDH Chemicals Ltd (Poole, Dorset, UK).  
Foetal bovine serum (FBS), penicillin-streptomycin (0.1g/L) and RPMI-1640 culture media were 
obtained from Gibco Life Technologies Ltd (Paisley, Strathclyde, UK).  Rat insulin standard was 
purchased from Novo Industria (Copenhagen, Denmark). Low nitrogen (40% (w/v)) sodium hydroxide 
was obtained from TE Laboratories Ltd. (Carlow, Ireland). Sulphuric acid (low nitrogen) was purchased 
from Lennox Laboratory Supplies Ltd (Dublin, Ireland). All other reagents including sodium hydroxide 
(32% w/v), DPP-IV, from porcine kidney (≥10 units/mg protein), Alcalase® 2.4L and Flavourzyme® 500L, 
amphotericin B, glutamine and the human caucasian colon adenocarcinoma (Caco-2) cells were 
purchased from Sigma Chemical Company Ltd. (Wicklow, Ireland). All synthetic peptides utilised were 




2.2. Generation of the boarfish protein hydrolysate at semi-pilot scale 
Minced deboned boarfish meat (720 kg) was thawed overnight at room temperature and suspended 
in 1,200 L H2O heated to 50 oC in a 6 m³ jacketed tank. The boarfish suspension at a protein 
concentration of 6.0% (w/v) at 50oC was adjusted to pH 7.0 with 32 % (w/v) NaOH. Alcalase 2.4L and 
Flavourzyme 500L were added at an enzyme-to-substrate ratio (E:S) of 0.67% (v/w) on a protein basis. 
The pH of the reaction mixture was maintained constant throughout hydrolysis by the addition of 32 
% (w/v) NaOH. After 3.75 h incubation at 50oC, the temperature of the suspension was increased to 
75 oC over 20 min and maintained at 75oC for a further 20 min. The protein/peptide components  were 
separated from the sediment and oil using a 2 step decanter/centrifugion process. The oil and 
sediment were first separated from the supernatant using a 3-phase decanter centrifuge (GEA, 
Düsseldorf, Germany). The supernatant was then further clarified using a continuous centrifuge (GEA, 
Düsseldorf, Germany) and the solution was cooled and stored overnight at 7°C. The clarified 
hydrolysate was pasteurised at 85oC for 85 s, evaporated to ~40% total solids and spray dried using an 
inlet and outlet temperature of 180 and 90oC, respectively. The spray-dried hydrolysate was stored in 
airtight containers until used.   
 
2.3. Protein quantification  
The protein equivalent content of the boarfish protein hydrolysate was determined using the macro-
Kjeldahl procedure as described previously by Connolly, Piggott and FitzGerald (2013) using a Nitrogen 
to protein conversion factor of 6.25 (Kristinsson & Rasco, 2000). All analyses were performed in 
triplicate. 
 
2.4. Simulated gastrointestinal digestion (SGID)  
SGID of the boarfish protein hydrolysate was performed as described by Walsh et al. (2004) with 
modifications. In brief, an aqueous solution of the hydrolysate at 2.0 % (w/v) on a protein equivalent 
basis was adjusted to pH 2 and incubated for 90 min at 37˚C with 2.5% (w/w) pepsin. The pH was then 
 
 
adjusted to pH 7 and the sample was incubated at 37˚C with 1% (w/w) Corolase PP for 150 min. 
Thermal inactivation of the enzyme was performed by heating at 80˚C for 20 min. 
 
2.5. In vitro quantification of DPP-IV inhibitory activity  
The DPP-IV inhibitory activity of hydrolysates and peptides was determined as described by Harnedy 
et al. (2015). Activity was expressed as mean IC50 value (inhibitory concentration that inhibits DPP-IV 
by 50%) ± SD from three independent replicates (n=3). Diprotin A (IPI) was used as a positive control. 
 
2.6. In situ quantification of DPP-IV inhibitory activity in Caco-2 cell 
The inhibition of DPP-IV in Caco-2 cells was determined according to the method described by Caron 
et al. (2017) with some modifications. Cells from passage 44 to 46 were used as a source of DPP-IV in 
this study. Caco-2 cells were grown at 37°C at 5% CO2 in minimum essential Eagle medium 
supplemented with 10% fetal bovine serum containing 100 U/mL penicillin, 100 μg/mL streptomycin, 
0.25 μg/mL amphotericin B and 2 mM glutamine. Following 5 d of growth the cells were trypsinised 
and seeded at a density of 20,000 cells/well in a 96-well optical black plate (Costar, Corning, NY, USA). 
After 16 h of contact, the culture medium was removed from the 96-well plate and cells were washed 
with 100 μL phosphate buffered saline (PBS, 0.01 M, pH 7.4). Fresh PBS (125 μL) was added to the well 
followed by 25 μL of each peptide solution or PBS (no inhibition control). Peptide solutions were 
prepared in PBS and assessed at concentrations ranging from 0.025 to 2.500 mM. The DPP-IV 
inhibition reaction was initiated by the addition of 50 μL of substrate (Gly-Pro-AMC) and the 
fluorescence was recorded every 2 min for 1 h using a plate reader (Biotek Synergy HT, USA) at 37°C. 
Excitation and emission wavelengths were at 360 and 460 nm, respectively. DPP-IV inhibition was 
defined as the percentage of DPP-IV activity inhibited by a given concentration of peptide compared 
to the control. Activity was expressed as mean IC50 value ± SD obtained from three independent 




2.7. Insulin secretion from BRIN‑BD11 cells 
The in vitro insulinotropic effects of protein hydrolysates and peptides were determined using clonal 
pancreatic BRIN-BD11 β-cells as described previously by Harnedy et al. (2018a). All analyses were 
performed in triplicate. The insulinotropic activity was expressed as the mean fold increase in the 
concentration of insulin secreted compared to the 5.6 mM glucose control for the hydrolysates 
analysed and as the mean insulin concentration secreted (ng/ml) for the peptides which were 
analysed. 
 
2.8. Fractionation of the SGID sample of the boarfish protein hydrolysate  
The hydrolysate was fractionated by semi-preparative reverse phase-high performance liquid 
chromatography (SP-RP-HPLC) using the method described by Harnedy et al. (2015) with 
modifications. An SGID treated sample of the boarfish protein hydrolysate was reconstituted to a 
concentration of 80 mg/mL in mobile phase A (HPLC-grade H2O) and 500 µL was injected onto a C18 
semi-preparative column (250 x 15 mm I.D., 10 µM particle size, Phenomenex, Cheshire, UK) attached 
to a C18 guard column (Phenomenex). The flow rate was set at 5 mL/min and the sample was 
separated using the following gradient (mobile phase B: 80% (v/v) ACN): 0–10 min: 0% B; 10-56 min: 
0-40% B; 56-61 min: 40-100% B; 61-66 min 100% B; 66-71 min: 100-0% B; 71–76 min 0% B. The 
absorbance of the eluent was monitored at 214 nm. Fractions eluting between 6-12, 12-15, 15-21, 21-
25, 25-29, 29-33 and 33-45 min were collected using a fraction collector (Waters, Milford, MA, USA) 
and dried using a solvent evaporator (Genevac, EZ-2 Plus, Genevac Ltd., Ipswich, UK). Aliquots of 
individual fractions with high activity (F26-29 and F13-15) were also collected every min and dried as 
described above. 
 
2.9. Peptide identification by UPLC-ESI-MS and MS/MS   
The most active semi-preparative RP-HPLC fractions, F28 and F29, were further separated using an 
ACQUITY UPLC (Waters, Milford, MA, USA) and analysed with a micrOTOF Q II mass spectrometer 
 
 
(Bruker Daltonics, Bremen, Germany). The peptide fractions were reconstituted to a concentration of 
0.1 mg/mL in mobile phase A (0.1% FA in HPLC grade H2O). Mobile phase B was 0.1% FA in 80% (v/v) 
ACN.  The flow rate was set at 0.2 mL/min. A 2 µL aliquot was injected onto an ACQUITY BEH 300 C18 
RP column (2.1 x 50 mm, 1.7 μm; Waters, Dublin, Ireland). Peptides were separated using the following 
gradient: 0–0.28 min: 0% B; 0.28-45 min: 0-80% B; 45-46 min 80-100% B; 46-48 min: 100% B; 48-
49 min 100-50% B; 49-50 min 50% B; 50-51 min: 50-0% B; 51-53 min: 0% B and the eluent was 
monitored at 214 and 280 nm.  The MS/MS methods employed for the identification of peptide masses 
were as previously described (O'Keeffe & FitzGerald, 2015; O'Keeffe, Norris, Alashi, Aluko, & 
FitzGerald, 2017). All MS/MS spectra were searched against the SwissProt Chordata database using 
PEAKS Studio 6.0 software (Bioinformatics Solution Inc, Waterloo, Canada).  De novo sequences 
generated using PEAKS Studio 6.0 software were searched for homology using an in-house database. 
The database consisted of 5,300 reviewed proteins from Actinopterygii, the superclass within which 
Capros aper (boarfish) is classified, along with 132 unreviewed protein sequences from the family 
Caproidae (boarfishes). 
 
2.10. Statistical analysis 
All statistical analyses were performed using the statistical software program SPSS (Version 22, IBM 
Inc., Chicago, IL, USA). Statistical significance at a level of p<0.05 was determined using one-way 
analysis of variance (ANOVA) followed by Tukey’s and Games–Howell post-hoc tests, where 
applicable. Furthermore, independent-samples T-tests were performed where applicable. 
 
3.0 Results and Discussion 
3.1. Bioassay-guided fractionation of peptides from the boarfish protein hydrolysate subjected to 
SGID 
As previously outlined, a boarfish protein hydrolysate generated at laboratory scale with Alcalase 2.4L 
and Flavourzyme 500L was shown to have good DPP-IV inhibitory and insulin stimulatory activity in 
 
 
vitro (Parthsarathy et al., 2019). The boarfish protein hydrolysate generated herein under similar 
conditions at semi-pilot scale using Alcalase 2.4L and Flavourzyme 500L also showed potent DPP-IV 
inhibitory (IC50: 1.46 ± 0.06 mg/mL) and insulin secretory activity from BRIN-BD11 cells (5.16 ± 0.27-
fold increase compared to 5.6 mM glucose control). Simulating in vitro gastrointestinal digestion is a 
commonly used approach to mimic gastric and intestinal digestion and to aid in determining the 
potential metabolic fate and alteration in bioactivity of functional food ingredients during digestion. 
The gastric enzyme pepsin and the intestinal enzyme preparation Corolase PP (containing trypsin, 
chymotrypsin and elastase) were utilised herein to mimic gastric and intestinal digestion, respectively. 
While static digestion models can provide information on the potential fate of peptides as they pass 
through the gastrointestinal tract, they have known limitations and cannot mimic the complex 
dynamics of the digestion process or the physiological interactions with the host in vivo (Brodkorb et 
al., 2019). For example, they do not mimic the variation in stomach pH following meal intake or the 
varying enzyme to substrate ratio, the gradual addition of gastrointestinal fluids, interactions with 
minerals within gastrointestinal fluids, gradual gastric emptying, the absorption of digestion products 
as they are produced and in addition they do not mimic digestion by gut microbiota. 
No significant difference (p>0.05) was observed in DPP-IV inhibitory and insulinotropic activities 
before and after SGID, with post-SGID activities for DPP-IV inhibition equal to an IC50 of 1.42 ± 0.06 
mg/mL and an insulin stimulatory activity equivalent to a 4.83 ± 0.49- fold increase versus the control. 
As shown in Supplementary Figure S1, no significant differences were observed in the overall peptide 
profile of the hydrolysate pre- and post-SGID. This indicated that the hydrolysate was resistant to 
gastrointestinal enzyme degradation. 
The SGID treated hydrolysate was fractionated by SP-RP-HPLC in order to identify those peptides 
potentially associated with the observed DPP-IV inhibitory and insulin secretory activities. As shown 
in Figure 1, the more hydrophobic fractions, F26-29, F30-33 and F34-45 had the most potent DPP-IV 
inhibitory activity when assessed at 1 mg/mL. F26-29 was shown to mediate significantly (p<0.05) 
more potent DPP-IV inhibitory activity (IC50: 0.26 ± 0.01 mg/mL) than F30-33 and F34-45 which had 
 
 
IC50 values of 0.32 ± 0.01 and 0.39 ± 0.00 mg/mL, respectively. Fractions 7 to 12 (F7-12) were taken at 
one min intervals (as opposed to a combined fraction) in the initial experiments as the hydrolysate 
contained a significant quantity of salt (4.99% (w/w)). As F26-29 showed significantly higher levels of 
DPP-IV inhibitory than all other fractions and had good insulin secretory activity, this region of the 
chromatogram (25-29 min) was further fractionated into 1 min fractions in order to assess the 
bioactivities of the individual fractions. F28 showed significantly higher (p<0.01) DPP-IV inhibitory 
activity (IC50 : 0.23 ± 0.01 mg/mL) than F26, F27 and F29, while F29 stimulated significantly higher 
(p<0.05) insulin secretory activity from BRIN-BD11 cells compared to F26, F27 and F29 (5.38 ± 0.42-
fold increase compared to the control).  
 
3.2. Identification and in vitro characterisation of anti-diabetic boarfish protein-derived peptides 
MS analysis was performed on F28 and F29 in an attempt to identify the peptides associated with the 
observed DPP-IV inhibitory and insulinotropic activity, respectively. The peptides identified using a 
database driven search (UniprotKB/SwissProt, limited to Chordata) and de novo sequencing in F28 are 
listed in Tables 1 and S1, respectively. The peptides identified in F29 in a similar manner are listed in 
Tables 2 and S2. Representative mass fragmentation spectra for three boarfish derived peptides are 
shown in supplementary data (Figure S2-4). A number of peptides identified in F28 and F29 (Tables 1 
and S1 and 2 and S2, respectively) were selected for chemical synthesis. The peptides from F28 and 
F29 which were synthesised for confirmatory DPP-IV inhibition studies from F28 and from F29 (which 
also showed good DPP-IV activity, Figure 1) were selected based on their homology to an in-house 
database and on the basis of structural features known to influence DPP-IV inhibitory activity 
(Nongonierma & FitzGerald, 2017). While reports have shown that amino acids such as glutamine, 
alanine, arginine, leucine, phenylalanine, valine, isoleucine and lysine have strong insulin secretory 
activity, limited information is available on the structure-activity relationship of insulinotropic 
peptides. In addition to homology to the in-house database, peptides containing all amino acids with 
 
 
known insulin secretory activity were selected from F29 for chemical synthesis. All synthetic peptides 
were initially screened for DPP-IV inhibitory (% inhibition) activity at 1500 µM and peptides showing 
inhibitory activity above 80% were further assessed to determine their IC50 values. As shown in Table 
3, twenty-two novel peptides with potent DPP-IV inhibitory activity (IC50 values <200 µM) were 
identified. The majority of these peptides contain a proline residue at the penultimate N-terminal 
position. This is in agreement with previous reports where the presence of proline at position 2 was 
shown to influence peptide DPP-IV inhibitory activity (Nongonierma & FitzGerald, 2016). Of all the 
peptides analysed, the highest DPP-IV inhibitory activity was observed with IPVDM, which had an IC50 
value of 21.72 ± 1.08 µM. To our knowledge, this peptide is the 3rd most potent DPP-IV inhibitory food 
protein-derived peptide identified to date, after IPI and VPL, which have IC50 values of 3.2 and 15.8 
µM, respectively (Nongonierma & FitzGerald, 2017). IPI was used as a positive control herein and the 
IC50 value obtained (3.49 ± 0.19 µM) was is in good agreement with that previously reported by 
Nongonierma et al. (2017). IPVDM contains isoleucine and proline in position 1 and 2, respectively. A 
number of tripeptides with IP at the N-terminus have also shown potent DPP-IV inhibitory activity. 
These include IPM, IPY, IPA and IPF which have IC50 values of 69.5, 38.749.0 and 47.3 µM, respectively 
(Nongonierma & FitzGerald, 2016; Cermeño et al., 2019; Nongonierma & FitzGerald, 2017; 
Nongonierma et al., 2019). As IPVDM has valine (which has a similar structure to isoleucine) in position 
3, the peptides IPV and IP were also synthesised and assessed for DPP-IV inhibitory activity with a view 
to determining the role of the N-terminal sequence on DPP-IV inhibitory activity as well as the role of 
leucine/isoleucine on same. IPV was highly potent with a DPP-IV IC50 value of 5.61 ± 0.20 µM. However, 
this activity was significantly lower (p<0.01) than that obtained for Diprotin A, i.e., IPI (3.49 ± 0.19 µM). 
IP had a DPP-IV IC50 of 112.40 ± 5.93 µM which was similar to that reported by Nongonierma & 
FitzGerald (2014). Other peptides identified herein with leucine/alanine in position 1, a proline in 
position 2 and valine in position 3 also showed potent DPP-IV inhibitory activity. These include LPVYD, 
LPVDM and APVP which had DPP-IV IC50 values of 51.36, 53.50 and 73.15 µM, respectively (Table 3). 
Cermeño et al. (2019) have also shown that similar peptides, IPVP and LPVP, derived from a brewers’ 
 
 
spent grain protein hydrolysate, possess good in vitro DPP-IV inhibitory activity with IC50 values of 
38.67 and 105.25 µM, respectively. Furthermore, for those peptides identified herein with proline at 
position 2 the presence of either isoleucine or leucine in certain positions was shown to have a 
significant effect on the DPP-IV inhibitory potency of the peptide. When isoleucine was at position 1 
the DPP-IV inhibitory activity was shown to be significantly higher than that mediated by the 
corresponding peptide with leucine at position 1 (e.g., IPGA/LPGA and IPVDM/LPDVM, p<0.001, (Table 
3)). A similar result was observed when either isoleucine or leucine was in position 3 (e.g., APIT/APLT 
and GPIN/GPLN, p<0.001 (Table 3)). Cermeño et al. (2019) also showed that peptides derived from a 
brewers’ spent grain protein hydrolysate with proline at position 2 had higher DPP-IV inhibitory 
activity when isoleucine was at position 1 and 3 compared to when leucine was present at these 
positions. The presence of either isoleucine or leucine at position 4 for the peptides identified herein 
appears to have no effect on DPP-IV inhibitory activity (e.g., GPGI/GPGL, TPGI/TPGL and GPSI/GPSL 
(p>0.05, Table 3)). In general, peptides with proline in position 2, which also contained 
posttranslational modifications, showed moderate to low DPP-IV inhibitory activity (Table 3).  While 
twenty-two of the peptides identified herein with DPP-IV IC50 values <200 µM were shown to be novel, 
two of the peptides, GPGL and LPGA, have previously been found within the sequence of marine 
(rotifer and grass carp)-derived antioxidant peptides: LLGPGLTNHA, GFGPGL and DLGLGLPGAH (Byun, 
Lee, Park, Jeon, & Kim, 2009; Cai et al., 2015).  
The use of an in vitro assay employing purified DPP-IV provides indicative information on the ability of 
a peptide to inhibit DPP-IV in a highly controlled environment. However, if peptides are to be used as 
functional food ingredients their efficacies need to be validated in vivo. Taking into consideration the 
financial and ethical costs of in vivo studies, Caron et al. (2017) developed a cell-based DPP-IV 
inhibition assay using human intestinal epithelial Caco-2 cells which express DPP-IV. This assay may 
provide some information on the potential fate of a peptide in vivo. It may also provide some 
information on the potential of the peptide to reach and thus inhibit soluble DPP-IV found in plasma. 
In this assay, intestinal mucosal conditions are simulated where peptides are required to pass through 
 
 
human intestinal cell membranes and resist degradation by brush border enzymes in order to mediate 
their activity. Peptides showing good DPP-IV inhibitory activity (IC50 values <200 µM) in the in vitro 
enzyme inhibition assay were therefore assessed for DPP-IV inhibitory activity in the in situ Caco-2 cell 
based assay. As shown in Table 3, lower, but in the majority of cases comparable, DPP-IV inhibitory 
activity was observed in the cell-based assay compared to the conventional in vitro assay. In contrast 
to the results reported by Caron et al. (2017), who observed similar DPP-IV inhibitory activity in both 
assays for the positive control IPI, a significantly higher IC50 value (p<0.001) was observed for IPI herein 
in the cell-based (9.93 ± 0.63 µM) compared to the in vitro assay (3.49 ± 0.19 µM, Table 3).  However, 
it must be noted that the enzyme utilised in the in vitro assay herein was porcine-derived DPP-IV. We 
have previously shown that the DPP-IV inhibitory activity of IPI when assessed using purified human 
DPP-IV (IC50: 5.00 ± 0.03 µM) was significantly lower (p<0.001) than that with the porcine enzyme (3.49 
± 0.19 µM, Table 3, Harnedy & FitzGerald, 2013). This was also shown with other peptides where 
Lacroix and Li-Chan (2015) reported that in general, porcine-derived DPP-IV was inhibited to a greater 
extent by protein-derived peptides than the human enzyme. While the sequence of DPP-IV is known 
to be highly conserved among mammalian species, the 12% difference in homology across the full 
porcine and human DPP-IV sequence and more specifically the 8% difference in homology between 
the sequence of the catalytic site may have an effect on activity (Lacroix, et al., 2015). The peptide 
which showed the highest DPP-IV inhibitory activity in the in vitro assay, IPVDM (IC50: 21.72 ± 1.08 
µM), also showed the highest activity in the cell-based assay (44.26 ± 0.65 µM). This indicates that 
IPVDM is potentially resistant to degradation by membrane associated peptidases. In contrast other 
peptides, e.g.., GPSI, were shown to mediate significantly lower activity in the cell-based assay (> 
312.50 µM) when compared to the in vitro assay (72.85 ± 1.66 µM). It is possible that these peptides 
were not efficiently transported across the cell membrane or were degraded during membrane 
transit. 
Six peptides all containing amino acid residues with known insulinotropic activity (VVVT, AVLQ, AVIQ, 
QQLA, QQIA and QF) along with peptides identified in F29 with high DPP-IV inhibitory activity in the in 
 
 
vitro assay were selected for assessment of their insulinotropic activity. As shown in Figure 2, VPDPR, 
GPGI, LPVDM, IPVDM, MPAVP, GPSL, GPSI, AVIQ and QQIA (all p<0.001), VPTP, APLER, GPIN, APVP (all 
p<0.01) and GPLN and VVVT (all p<0.05) stimulated a significantly higher insulinotropic response from 
BRIN BD11 cells (1.3 to 1.7-fold increase) when assessed at 10-6 M compared to the control (5.6 mM 
glucose) which secreted 3.93 ± 0.26 ng/mL of insulin. To our knowledge, none of these peptides have 
previously been reported to mediate insulinotropic activity. Furthermore, three peptides (IPVDM, 
MPAVP and GPSL) stimulated the secretion of significantly (p<0.001) higher concentrations of insulin 
from BRIN-BD11 cells compared to the control when assessed at a lower concentration (10-10 M, data 
not shown). All three peptides (in particular IPVDM) also showed potent DPP-IV inhibitory activity 
(Table 3). This would suggest that peptides such as IPVDM may contribute to glycaemic control by 
multiple mechanisms. These include direct or indirect stimulation of insulin secretion due to the 
presence of higher levels of circulating active GLP-1 arising from peptide mediated inhibition of DPP-
IV. As previously stated, amino acids such as glutamine, alanine, arginine, leucine, phenylalanine, 
valine, isoleucine and lysine have been shown to mediate potent insulin secretory activity. However, 
of the six peptides tested (which were composed entirely of known insulin secretory amino acids), 
only three showed significantly higher insulin secretory activity compared to the control when 
assessed at 10-6 M (Figure 2). These include AVIQ and QQIA (p<0.001), and VVVT (p<0.05). 
Nevertheless, this activity was lower than the activity mediated by specific peptides containing ≤ 2 
amino acids with known insulinotropic activity (e.g., VPDPR, GPGI, IPVDM, MPAVP, GPSL, GPSI). To 
date there are two reports on peptides identified from food proteins which show insulin secretory 
activity from BRIN BD11 cells (Drummond et al., 2018; O’Harte et al., 2016). No information is as yet 
available on the structure-activity relationship of insulinotropic peptides. While no definite 
interpretations can be drawn on the structure activity relationship of food-derived insulinotropic 
peptides, some preliminary observations can be made based on the results presented herein. 
Comparing the activity of IPVDM and LPVDM, it was seen that IPVDM had higher mean insulinotropic 
activity, albeit not significant, than LPVDM. A similar result was observed with peptides identified from 
 
 
a Palmaria palmata protein hydrolysate where ILAP was shown to exhibit higher insulin secretory 
activity than LLAP (O’Harte et al., 2016). For sequences such as AVLQ/AVIQ and QQLA/QQIA where 
leucine/isoleucine is in position 3, peptides with isoleucine in that position had significantly higher 
(p<0.01) insulin secretory activity than corresponding peptides with leucine at this position. When the 
activity mediated by PAVP was compared to APVP and MPAVP, significantly lower (p<0.001) 
insulinotropic activity was observed with PAVP compared to that observed with APVP and MPAVP . 
 
4. Conclusion 
Peptides showing potent in vitro DPP-IV inhibitory activity (in a conventional in vitro and in a cell-based 
in situ assay) and insulin secretory activity from cultured pancreatic BRIN-BD11 cells were released 
from boarfish muscle protein following hydrolysis at semi-pilot scale using Alcalase 2.4L and 
Flavourzyme 500L. Confirmatory studies with synthetic peptides identified 22 novel DPP-IV inhibitory 
peptides with IC50 values <200 µM along with 15 novel insulinotropic peptides. The DPP-IV inhibitory 
peptide, IPVDM, which showed potent DPP-IV inhibitory activity in the in vitro assay also showed 
potent activity in a cell-based DPP-IV inhibitory assay. Furthermore, IPVDM, mediated potent insulin 
secretory activity from cultured pancreatic BRIN-BD11 cells. These results indicate that IPVDM may be 
transported across the human epithelial cell membrane in an intact form and that it may mediate anti-
diabetic effects in vivo via multiple mechanisms. However, further studies are required to evaluate 
the in vivo anti-diabetic activity of this peptide and other peptides identified herein. 
The successful transfer of the hydrolysis process from laboratory to semi-pilot scale and stabilisation 
of the peptides through spray-drying would indicate that the boarfish protein-derived hydrolysate 
herein can be manufactured at industrial scale and may be employed as a functional ingredient for 
the prevention and management of T2DM. Furthermore, the value of boarfish, a protein rich 
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Table 1 Sequences of the peptides (with flanking N and C terminal residue) identified by liquid 
chromatography-mass spectrometry/mass spectrometry in boarfish (Capros aper) protein hydrolysate 













Creatine kinase U-type, mitochondrial:       
Sus scrofa (Q29577) 
396.6825 2 -7.2 6.23 
L.TEAPLNPK.A 
Actin, gamma-enteric smooth muscle:   
Gallus gallus (P63270) 
435.2393 2 -1.6 7.89 
T.GIVLD.S 516.2890 1 -26.7 12.4 
E.KSYELPDGQ.V 518.7515 2 1.2 10.32 
W.LPVYD.A 
Myosin heavy chain, fast skeletal muscle: 
Cyprinus carpio (Q90339) 
303.6599 2 -1.4 11.51 
Y.DYPMIS.Q 725.3174 1 0.0 13.22 
A.DSKPGSI.R 
Nucleoside diphosphate kinase B:   
Merluccius senegalensis (P85282) 
352.1855 2 2.4 6.85 
T.NPADSKPGSI.R 493.2503 2 -1.6 8.29 
ppm: mass error, calculated as 106 × (experimental mass - theoretical mass) / theoretical mass. *Peptides 















Table 2 Sequences of the peptides (with flanking N and C terminal residue) identified by liquid 
chromatography-mass spectrometry/mass spectrometry in boarfish (Capros aper) protein hydrolysate 













Actin, gamma-enteric smooth muscle:   
Gallus gallus (P63270) 
435.2436 2 8.3 7.72 
K.YPIEH(+14.02).G 336.6758 2 13.6 8.07 
S.YELPDGQVIT. I 567.7916 2 7.3 14.99 
K.SYELPDGQVIT. I  611.3044 2 1.5 15.1 
A.AFPPDVAGN.V 
Myosin regulatory light chain 2, skeletal 
muscle isoform: Gallus gallus (P02609) 
444.2211 2 10.4 14.63 
W.AAFPPDVAGN.V 958.4749 1 12.5 15.15 
T.NPADSKPGSI.R 
Nucleoside diphosphate kinase B:   
Merluccius senegalensis (P85282) 
493.2527 2 3.3 8.35 
I.YERPDFGGQ.M 
Beta-crystallin S-2: Chiloscyllium indicum 
(P48647) 
534.7458 2 9.4 10.4 
ppm: mass error, calculated as 106 × (experimental mass - theoretical mass) / theoretical mass. *Peptides 















Table 3 Dipeptidyl peptidase-IV (DPP-IV) inhibitory activities of synthetic boarfish (Capros aper) 
protein-derived peptides obtained using in vitro and in situ (Caco-2 cell) DPP-IV inhibitory assays. 
Peptide* 
In vitro assay In situ assay 
Inhibition (%) at 1500 µM IC50 (µM) IC50 (µM) 
IPI (+ve control) n.d. 3.49 ± 0.19 9.93 ±  0.63 
IPVDM 99.47 ± 0.46 21.72 ± 1.08 44.26 ± 0.65 
APIT 96.52 ± 0.78 34.73 ± 4.66 123.40 ± 7.50 
VPTP 100 ± 1.00 38.93 ± 2.65 66.68 ± 2.18 
GPIN 97.97 ± 1.34 48.96 ± 3.93 111.40 ± 7.21 
LPVYD 97.76 ± 1.89 51.36 ± 3.61 60.63± 1.84 
LPVDM 97.79 ± 0.88 53.50 ± 6.31 150.80 ± 5.44 
APLER 98.66 ± 1.23 63.67 ± 5.40 153.10 ± 2.69 
IPGA 98.66 ± 0.67 66.37 ± 3.84 96.32 ± 5.93 
GPSL 95.73 ± 0.47 68.13 ± 2.79 227.63 ± 6.90 
GPSI 94.86 ± 1.09 72.85 ± 1.66 > 312.5  
APVP 96.39 ± 0.53 73.15 ± 3.09 284.65 ± 3.32 
VPDPR 99.85 ± 1.46 79.10 ± 2.67 128.90 ± 4.95 
APLDK 94.87 ± 1.06 90.37 ± 1.70 223.90 ± 4.38 
APLT 95.61 ± 3.81 91.10 ± 11.11 165.55 ± 4.17 
MPAVP 93.67 ± 2.36 115.27 ± 4.21 149.70 ± 13.44 
GPGI 90.89 ± 1.93 116.27 ± 8.60 307.30 ± 2.69 
GPLN 92.34 ± 1.84 116.37 ± 9.97 > 312.5 
PAVP 88.91 ± 1.65 126.51 ± 2.54 > 312.5 
GPGL 92.59 ± 0.89 131.90 ± 8.44 245.50 ± 1.98 
LPGA 95.03 ± 0.77 154.12 ± 7.04 245.45 ± 13.65 
AALP 80.00 ± 1.11 164.37 ± 18.78 > 312.5 
TPTV 91.05 ± 2.11 164.52 ± 19.75 177.00 ± 10.61 
AAIP 82.40 ± 1.80 251.58 ± 24.47 n.d. 
YPL{pSER}L 89.77 ± 4.35 261.46 ± 1.17 n.d. 
TPGI 87.41 ± 3.06 282.16 ± 12.89 n.d. 
TPGL 85.00 ± 1.97 297.41 ± 13.02 n.d. 
YPII{pSER} 83.48 ± 2.50 300.67 ± 11.29 n.d. 
YPIL{pSER} 84.28 ± 2.72 302.47 ± 18.19 n.d. 
ISAP 80.88 ± 0.90 393.88 ± 22.16 n.d. 
YPL{pTHR}V 81.17 ± 1.21 511.47 ± 6.36 n.d. 
YPLV{pTHR} 80.55 ± 3.86 508.37 ± 33.43 n.d. 
ISGP 66.63 ± 0.92 n.d. n.d. 
LSAP 57.88 ± 3.34 n.d. n.d. 
GALP 44.59 ± 1.90 >1500 n.d. 
GAIP 43.46 ± 1.42 >1500 n.d. 
IGGP 43.25 ± 2.03 >1500 n.d. 
LGGP 39.58 ± 4.06 >1500 n.d. 
LSGP 38.11 ± 2.28 >1500 n.d. 
GLAGQ 18.04 ± 3.42 >1500 n.d. 
SAGIH 8.30 ± 0.93 >1500 n.d. 
 
 
SAGLH 6.05 ± 0.79 >1500 n.d. 
AAPF 4.54 ± 4.42 >1500 n.d. 
FDLP n.a. >1500 n.d. 
FDIP n.a. >1500 n.d. 
LDFP n.a. >1500 n.d. 
IDFP n.a. >1500 n.d. 
GGLP n.a. >1500 n.d. 
GGIP n.a. >1500 n.d. 
VVVT n.a. >1500 n.d. 
AVLQ n.a. >1500 n.d. 
AVIQ n.a. >1500 n.d. 
QQLA n.a. >1500 n.d. 
QQIA n.a. >1500 n.d. 
QF n.a. >1500 n.d. 
Mean ± SD (n=3). % inhibition studies were performed at 1500 µM. IC50: inhibitory concentration that inhibits enzyme 





Figure 1. Semi-preparative reversed phase-high performance liquid chromatography profile of the boarfish (Capros aper) protein hydrolysate subjected to 
simulated gastrointestinal digestion along with the dipeptidyl peptidase-IV (DPP-IV) inhibitory and insulin secretory activity of the associated pooled and 
individual fractions (F7-F45). Samples were tested for in vitro DPP-IV inhibition and insulin secretory activity by pancreatic BRIN-BD11 cells at a 
concentration of 1.00 and 1.25 mg/mL, respectively. DPP-IV inhibitory data is displayed as % inhibition and as an IC50 value (inhibitory concentration that 
inhibits enzyme activity by 50 %) for selected fractions. Insulin secretory activity was expressed as fold increase compared to the control (5.6 mM glucose). 
Values (mean ± SD, n=3) with different superscript letters are significantly different at p<0.05. 
 
Fraction DPP-IV 







     
F7 15.11 ± 2.00g - 4.83 ± 0.82 a      
F8 13.75 ± 1.17g - 3.83 ± 0.70 b      
F9 29.18 ± 1.43f - 5.04 ± 0.49 a      
F10 42.35 ± 2.05e - 2.33 ± 0.34 c      
F11 57.74 ± 2.68cd - 1.25 ± 0.15 d      
F12 56.33 ± 1.36cd - 1.00 ± 0.10 d      
F13-15 54.17 ± 1.57d - 4.71 ± 0.43 a  Fraction DPP-IV inhibition at 
1 mg/ml (%) 
DPP-IV IC50 
(mg/ml) 
Insulin secretion (fold 
increase v control) F16-21 58.95 ± 1.82cd - 4.27 ± 0.34 a  
F22-25 61.47 ± 2.54c - 4.71 ± 0.38 a  F26 76.10 ± 0.32 0.40 ± 0.01c -0.50 ± 0.05 d 
F26-29 86.21 ± 3.03a 0.26 ± 0.01a 4.71 ± 0.32 a  F27 82.35 ± 1.04 0.27 ± 0.01b 4.08 ± 0.48 b 
F30-33 80.08 ± 3.06ab 0.32 ± 0.01b 4.07 ± 0.27 a  F28 83.09 ± 2.08 0.23 ± 0.01a 1.50 ± 0.12 c 
F34-45 77.48 ± 3.87b 0.39 ± 0.00c 1.07 ± 0.11 d  F29 83.09 ± 1.04 0.27 ± 0.00b 5.38 ± 0.42 a 
 
 
Figure 2: Insulin secretion from pancreatic BRIN-BD11 cells for selected synthetic boarfish (Capros aper) protein hydrolysate-derived peptides when tested 
at 10-6 M. Values are expressed as mean  SD. (n=6). *p< 0.05, **p< 0.01 and ***p<0.001 compared to the 5.6 mM glucose control. Positive control: 









Figure S1: Reverse phase ultra-performance liquid chromatography profiles of the boarfish (Capros caper) protein hydrolysate (BFPH) before and after 







Figure S2: Mass fragmentation spectrum for the boarfish (Capros aper) derived peptide Leu/Ile-Pro-Val-Asp-Met (m/z 574.2983). The x-axis represents the 1 



























Figure S3: Mass fragmentation spectrum for the boarfish (Capros aper) derived peptide Pro-Ala-Val-Pro (m/z 383.2328). The x-axis represents the m/z at 12 



























Figure S4: Mass fragmentation spectrum for the boarfish (Capros aper) derived peptide Ala-Pro-Leu/Ile-Thr (m/z 383.2328). The x-axis represents the m/z at 23 



























Table S1: Sequences of the peptides identified by liquid chromatography-mass spectrometry/mass spectrometry in boarfish (Capros aper) protein hydrolysate 34 
fraction 28 (F28) using the de novo sequencing function of PEAKS software.   35 






Homologous Protein: Species 
LELP 96 471.2733 1 14.57 -17.1 numerous 
LEIP      numerous 
IELP      numerous 
IEIP      numerous 
VGGM 94 363.1657 1 6.48 -10.8 numerous 
AGLT 94 361.2066 1 5.58 -4.2 numerous 
AGIT      numerous 
EAPPHL 94 332.1736 2 9.46 -9.2 - 
EAPPHI      myosin heavy chain, fast skeletal muscle: Cyprinus carpio  
VGVT 94 375.2198 1 5.99 -10.7 numerous 
DLAPK 94 272.1596 2 5.47 -3.1 - 
DIAPK      kynurenine formamidase: Salmo salar 
DPTNLK 93 344.1844 2 5.98 -8.1 - 
DPTNIK      - 
NSLM 93 464.2145 1 9.26 -6.2 numerous 
NSIM      actin, cytoplasmic 1: numerous species 
WYPR 93 311.1507 2 5.5 -32.6  - 
VDLK 93 237.6465 2 5.96 -13.5 numerous 
VDIK      numerous 
LTLLP 92 556.3253 1 15.09 -81.2 
G-protein coupled receptor: Danio rerio / Homeobox protein SEBOX: 
Danio rerio  
ITIIP      - 
LTILP      numerous 
LTLIP      Cytoplasmic tRNA 2-thiolation protein 2: Danio rerio  
ITLIP 
      
Leucine-rich repeat-containing G-protein coupled receptor 6: Danio rerio / 




ITILP      G-protein coupled receptor 98: Danio rerio 
ITLLP      - 
ITLLP      - 
LTLLP 
      
G-protein coupled receptor 98: Danio rerio/ homeobox protein SEBOX: 
Danio rerio 
LDLL 92 473.2923 1 16.07 -9.8 numerous 
IDII      numerous 
LDIL      numerous 
LDLI      numerous 
IDLI      numerous 
IDIL      numerous 
IDLL      numerous 
IDLL      numerous 
EAPPLH 91 332.1935 2 9.35 51.0 - 
EAPPIH      - 
ASLP 91 387.2196 1 8.97 -10.9 numerous 
ASIP      numerous 
ANPL 91 414.2303 1 8.46 -10.6 numerous 
ANPI      numerous 
NQLP 91 471.2747 1 14.92 39.5 numerous 
NQIP      numerous 
GSLP 90 373.2065 1 8.64 -4.5 numerous 
GSIP      numerous 
KDVLA 90 273.1659 2 6.63 -8.9 numerous 
KDVIA 
      
multidrug and toxin extrusion protein 1: Danio rerio/ 
dihydropyrimidine dehydrogenase [NADP(+)]: Danio rerio 
MNTPGVP 89 358.1877 2 7.8 33.3 - 
DAGPGPPAA 89 376.7006 2 6.55 48.7 - 
APLT 89 401.235 1 6.05 -11.2 numerous 




RDNPGHP 89 396.6825 2 6.23 -21.4 - 
LEKML 88 317.1674 2 5.25 -57.7 numerous 
IEKML 
      
coatomer subunit beta: Danio rerio/ hypoxia-inducible factor 1-alpha 
inhibitor: Danio rerio 
LEKMI       - 
IEKMI       - 
VGSL 88 375.2209 1 7.92 -7.8 numerous 
VGSI      numerous 
AGGF 86 351.1627 1 7.53 -10.1 numerous 
DPTKAR 86 344.1836 2 6.1 -27.0 - 
TVPPLH 86 332.175 2 9.38 -60.0 - 
TVPPIH      - 
VPTP 86 413.2347 1 8.08 -11.5 numerous 
EAPFSL 86 332.1767 2 9.72 17.1 - 
EAPFSI      - 
NAGKQP 86 307.6763 2 8.47 32.0 - 
VDYKN 85 319.6578 2 4.64 -9.5  - 
SLGP 85 373.2069 1 8.17 -3.4 numerous 
SIGP      numerous 
DYSPM 85 306.6379 2 6.45 57.4  - 
FVSQV 85 290.1575 2 7.94 -10.3 numerous 
LANDPF 85 338.6689 2 14.91 0.6 - 
IANDPF      - 
LVLD 84 459.2757 1 11.4 -12.3 numerous 
LVID      numerous 
IVID      numerous 
IVLD      numerous 
NNLVP 84 556.3298 1 15.13 37.7  - 
NNIVP       - 




ISGP      numerous 
EGYPR 83 311.1491 2 5.46 -13.2  - 
AVSP 83 373.205 1 7.44 -8.4 numerous 
DNLAPM(+15.99) 83 338.6661 2 14.8 41.3 - 
DNIAPM(+15.99)      - 
DGYPR 83 304.1445 2 5.42 -2.9 adenylate kinase isoenzyme 1: Cyprinus carpio 
LSAP 83 387.219 1 9.05 -12.4 numerous 
ISAP      numerous 
M(+15.99)NCCPF 83 365.6281 2 15.13 18.0 cornifelin homolog: Danio rerio 
SGLP 83 373.2023 1 8.71 -15.7 numerous 
SGIP      numerous 
VAAGQ 82 445.2364 1 5.22 -9.3  - 
ILGSPT 82 294.1599 2 5.21 -46.5 pigment-dispersing hormone: Faxonius limosus  
LLGSPT      - 
IIGSPT      - 
LIGSPT      tRNA modification GTPase GTPBP3, mitochondrial: Danio rerio  
AAPF 82 405.2118 1 13.59 -3.4 numerous 
DSRPAP 82 321.6737 2 5.69 30.5 - 
MTLCDT 82 342.1868 2 8.87 135.5 - 
MTICDT      - 
LDAHGP 82 305.1502 2 6.09 -9.9 estrogen receptor: Oreochromis aureus  
IDAHGP      - 
ATAGGAPHE 82 405.6897 2 5.29 -2.4 - 
LEKPM(+15.99) 82 317.1666 2 5.2 -2.5 transmembrane protein 201: Danio rerio  
IEKPM(+15.99)      myosin heavy chain, fast skeletal muscle: Cyprinus carpio  
LELM 81 505.2676 1 14.01 -2.8 numerous 
LEIM      numerous 
IELM      numerous 
IEIM      numerous 




M(+15.99)DLP 81 491.2467 1 15.89 60.5 numerous 
M(+15.99)DIP      numerous 
LGAGQ 81 445.2359 1 5.25 -10.3 numerous 
IGAGQ       - 
LLM(+15.99)S 81 479.2595 1 8.55 12.7 numerous 
IIM(+15.99)S      numerous 
LIM(+15.99)S      numerous 
ILM(+15.99)S      numerous 
QF 81 294.1429 1 7.91 -6.7 numerous: Capros aper  
R 81 175.1172 1 0.86 -9.9 numerous: Capros aper  
TEAPLNPK 81 435.2422 2 7.72 5.1 actin, cytoplasmic 1 : Salmo salar  
TEAPINPK      - 
NLGPQGPK 81 405.6874 2 5.37 -97.8 - 
NIGPQGPK      - 
F 80 166.0864 1 7.7 0.8 numerous: Capros aper  
VAVEV 80 516.2968 1 12.53 -11.8 numerous 
NPADSKKPE 80 493.2503 2 8.29 -1.6 - 
LPGA 80 357.2119 1 5.68 -3.8 numerous 













V(D)J recombination-activating protein 1: Danio rerio and Oncorhynchus 
mykiss  
HIISIT       - 
HLLSIT       - 
HILSIT       - 
HLISIT       - 
HIISLT       - 
HILSLT       - 
HLISLT       - 




ppm: mass error, calculated as 106 × (experimental mass - theoretical mass) / theoretical mass. ‘-‘ : peptides did not show homology with the protein sequences of in the 37 
‘in-house’ database which consisted of 5,300 reviewed proteins from the superclass Actinopterygii and 132 unreviewed protein sequences from the family 38 




































Table S2: Sequences of the peptides identified by liquid chromatography-mass spectrometry/mass spectrometry in boarfish (Capros aper) protein 72 
hydrolysate fraction 29 (F29) using the de novo sequencing function of PEAKS software.   73 






Homologous Protein: Species 
LDLL 96 473.3015 1 16.15 9.6 numerous 
IDII      numerous 
LDIL      numerous 
LDII      numerous 
LDLI      numerous 
IDLI      numerous 
IDIL      numerous 













sarcoplasmic/endoplasmic reticulum calcium ATPase 1: Makaira 
nigricans/ Serine/threonine-protein kinase SIK3 homolog: Danio rerio  
VVVT 96 417.2753 1 7.04 10.9 numerous 
VPTP 94 413.2453 1 8.11 14.2 numerous 
VGVT 94 375.2275 1 6.07 10.0 numerous 
VLVS 94 417.2761 1 7.66 12.9 numerous 
VIVS      numerous 
TGLP 93 387.2267 1 9.06 7.6 numerous 
TGIP      numerous 
ALDLL 92 544.3345 1 16.83 0.8 numerous 
AIDII      triple functional domain protein: Danio rerio 
ALDLI      numerous 
ALDIL      numerous 
ALDII 
      
nipped-B-like protein A: Danio rerio/TATA box-binding protein-like protein 
1: Danio rerio 
AIDLL      ubiquitin carboxyl-terminal hydrolase 22: Danio rerio 
AIDIL      numerous 




LEAPPH 92 332.1832 2 7.51 19.9 - 
IEAPPH      myosin heavy chain, fast skeletal muscle: Cyprinus carpio  
GHREP 92 298.1542 2 2.02 10.8  - 
VELK 92 244.6606 2 5.9 12.4 numerous 
VEIK      numerous 
PAVP 92 383.2328 1 6.6 10.3 numerous 
TVPPHL 92 332.1823 2 9.48 -37.8 - 
TVPPHI      - 
APLDK 91 272.1653 2 5.09 17.6 alcohol dehydrogenase class-3 chain L: Gadus morhua  
APIDK       - 
WYPR 91 311.1566 2 5.73 -13.7  - 
LGVDK 91 266.1653 2 6 18.4  - 
IGVDK       - 
TVGALPT 91 329.6837 2 6.92 -25.7 - 













filamin A-interacting protein 1-like: Danio rerio/tail-anchored protein 
insertion receptor WRB: Danio rerio  
APIER       - 
TEAPLNPK 90 435.2436 2 7.72 8.3 actin, gamma-enteric smooth muscle: Gallus gallus  
YSGL 90 439.2249 1 10 14.2 numerous 
YSGI      numerous 
FDLP 90 491.254 1 15.68 8.2 numerous 
FDIP      numerous 
AALP 90 371.2334 1 9.43 12.2 numerous 
AAIP      numerous 
VPDAPK 90 313.6839 2 6.07 15.6 - 
LDLK 90 244.6597 2 6.09 8.9 numerous 
IDLK      numerous 
LDIK      numerous 




VSYPR 90 311.158 2 5.77 -43.2  - 
AGLP 90 357.2167 1 9.14 9.7 numerous 
AGIP      numerous 
GPGL 89 343.2014 1 8.67 11.3 numerous 
GPGI      numerous 
TPGL 89 387.2273 1 9.6 9.1 numerous 
TPGI      numerous 
TTGLV 89 490.2935 1 9.53 12.9 - 
TTGIV      numerous 
GLAGQ 89 445.2464 1 5.36 13.3 numerous 
GIAGQ      polycystin-2: Oryzias latipes 
LWAAP 88 279.1724 2 5.7 52.6 - 
IWAAP      - 
SGLP 88 373.2132 1 8.47 13.6 numerous 
SGIP      numerous 
TPTV 88 417.2749 1 7.2 97.3 numerous 
ASLP 88 387.2277 1 9.15 10.2 numerous 
ASIP      numerous 
GSLP 88 373.21 1 9.04 4.9 numerous 
GSIP      numerous 
LGGV 88 345.2169 1 8.14 10.8 numerous 
IGGV      numerous 
SGELGLQLK 88 472.7416 2 7.22 -69.0 - 
SGEIGIQIK      - 
SGELGLQIK      - 
SGELGIQLK      - 
SGEIGLQIK      - 
SGEIGIQLK      - 
SGELGIQIK      - 




ANLP 88 414.2394 1 8.7 11.5 numerous 
ANIP      numerous 
GHRPE 88 298.1543 2 2.1 11.0 - 
APLSTP 88 293.1756 2 5.44 33.7 - 
APISTP      - 
LGGP 87 343.2006 1 8.3 8.9 numerous 
IGGP      numerous 
MNPEPQ 87 358.1965 2 7.97 109.0 - 
ELLEKDL 87 430.2334 2 11.55 -20.4 - 
EIIEKDI      - 
ELLEKDI      - 
ELIEKDL      - 
EILEKDI      - 
EIIEKDL      - 
ELIEKDI      - 
EILEKDL      - 
LDFP 86 491.2557 1 16.13 11.6 numerous 
IDFP      numerous 
SAGIH 86 242.6318 2 4.01 10.2 actin, alpha skeletal muscle: numerous 
SAGLH      homeobox protein Hox-A3a: Danio rerio  
EAPPLH 86 332.1812 2 9.68 13.7 - 
EAPPIH      - 
GGLP 86 343.2028 1 8.56 15.1 numerous 
GGIP      numerous 
VSVGQVP 86 343.2037 2 6.89 17.9 - 
GPLN 86 400.2238 1 5.4 12.0 numerous 
GPIN      numerous 
LPVDM 86 574.2983 1 13.34 13.7 numerous 
IPVDM      numerous 




AVIQ      numerous 
LLKDGDK 85 263.4919 3 5.13 12.8 - 
IIKDGDK      - 
LIKDGDK      - 
ILKDGDK      - 
MPTAAP 84 294.1776 2 7.73 105.9 - 
VDIK 84 237.6528 2 6 13.1 numerous 
VDLK      numerous 
EAPFSL 84 332.1817 2 9.78 32.1 - 
EAPFSI      - 
YPLS(+79.97)L 84 336.6763 2 8.18 66.9 guanine nucleotide-binding protein subunit beta-5a & b: Danio rerio 
YPLS(+79.97)I      - 
YPIS(+79.97)I      - 
YPIS(+79.97)L      - 
MPAVP 84 257.6586 2 6.47 79.0 neurexin-1a: Danio rerio  
VVVP 84 413.2444 1 8.31 -76.3 numerous 
LELL 83 487.3111 1 16.43 -3.2 numerous 
IEII      numerous 
LEIL      numerous 
LELI      numerous 
IELI      numerous 
IEIL      numerous 
LEII      numerous 













pre-mRNA-splicing factor SLU7: Danio rerio/TBC1 domain family member 
8B: Danio rerio 
IGGM 83 377.1893 1 9.12 10.6 numerous 
LGGM      numerous 
YPIIS(+79.97) 82 336.6764 2 7.92 67.3 numerous 




YPILS(+79.97)      DANRE Uracil phosphoribosyltransferase homolog: Danio rerio  
YPLIS(+79.97)      - 
LRDK 82 266.1638 2 6.1 -8.6 numerous 
IRDK      numerous 
ELLMVPQ 82 415.2512 2 10.86 55.8 - 
EIIMVPQ      - 
ELIMVPQ      - 
EILMVPQ      - 
NYSDL 82 306.1496 2 6.71 40.6 DANRE Hyccin: Danio rerio  
NYSDI      - 
GPSL 82 373.2125 1 8.86 11.7 numerous 
GPSI      numerous 
LM(+15.99) 82 279.1418 1 3.29 16.2 numerous 
IM(+15.99)      numerous 
EAPPHL 82 332.1817 2 9.73 15.3 - 
EAPPHI      myosin heavy chain, fast skeletal muscle: Cyprinus carpio  
QQLA 82 459.2613 1 6.67 11.2 numerous 
QQIA      numerous 
LPVVDGW 81 393.2249 2 9.62 29.7 - 
IPVVDGW      - 
WVSVQGP 81 386.7188 2 7.5 40.7 - 
KNAPPH 81 332.1805 2 7.56 -5.4 - 
TVLMTV 81 332.1814 2 9.84 -28.7 - 
TVIMTV      - 
YPLT(+79.97)V 81 336.6764 2 7.86 67.2 growth/differentiation factor 8: numerous 
YPIT(+79.97)V      - 
FVEP 80 491.2587 1 16.38 17.7 numerous 
VFLD 80 493.2671 1 12.93 3.0 numerous 




YPLVT(+79.97) 80 336.6752 2 7.97 63.5 
DANRE Pleckstrin homology domain-containing family H member 1: Danio 
rerio 
YPIVT(+79.97)      - 
AVLGER 80 322.6761 2 6.11 -42.9 - 
AVIGER      - 
NYSPM 80 306.1514 2 6.67 75.6 - 
QF 80 294.1482 1 7.98 11.5 numerous 
DLLL 80 473.3022 1 16.04 11.2 numerous 
DIII      numerous 
DLIL      numerous 
DLLI      numerous 
DLII      numerous 
DIIL      numerous 
DILI      numerous 
DILL      numerous 
WWQVGP 80 386.7183 2 7.69 66.9 - 
GALP 80 357.2178 1 8.97 12.9 numerous 
GAIP      numerous 
APVP 80 383.2314 1 7.57 6.6 numerous 
VSVGNLP 80 343.2017 2 6.95 12.1 - 
VSVGNIP      - 
ALC: Average local confidence is an average of the individual local confidence score for each amino acid and is based on the PEAKS algorithm (Ma et al., 2003).  74 
ppm: mass error, calculated as 106 × (experimental mass - theoretical mass) / theoretical mass. ‘-‘ : peptides did not show homology with the protein sequences of in the 75 
‘in-house’ database which consisted of 5,300 reviewed proteins from the superclass Actinopterygii and 132 unreviewed protein sequences from the family 76 
Caproidae (boarfishes). *Peptides displayed using one letter code for the amino acids. 77 
 78 
 79 
 80 
